positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients. Late yesterday evening, Sorrento Therapeutics Inc. (SRNE:NASDAQ)announced

Idk if its because I’m on a cell, but I’m still having difficulty posting.

$SRNE Sorrento’s – new – RESPI-STIX – Will be able to tell you if you have the FLU, Covid or both. “Medical diagnostic test kits for the clinical detection of Influenza A, Influenza B, Covid-19 and Coronavirus featuring lateral flow tests; Influenza A, Influenza B, COVID-19 and Coronavirus lateral flow viral antigen diagnostic test” RESPI-STIX Trademark link: uspto.report/TM/https://uspto.report/TM/9046211690462116

$SRNE Sorrento Therapeutics, Inc. (NASDAQ: SRNE) was initiated with a Buy rating and a $26 price target at B. Riley Securities. The stock was trading at $28.67, in a 52-week range of $1.55 to $19.39. The consensus price target is $28.67.